0001140361-22-021621.txt : 20220602 0001140361-22-021621.hdr.sgml : 20220602 20220602163028 ACCESSION NUMBER: 0001140361-22-021621 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220602 DATE AS OF CHANGE: 20220602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ocuphire Pharma, Inc. CENTRAL INDEX KEY: 0001228627 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113516358 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-34079 FILM NUMBER: 22991233 BUSINESS ADDRESS: STREET 1: 37000 GRAND RIVER AVE. STREET 2: SUITE 120 CITY: FARMINGTON HILLS STATE: MI ZIP: 48335 BUSINESS PHONE: 248-681-9815 MAIL ADDRESS: STREET 1: 37000 GRAND RIVER AVE. STREET 2: SUITE 120 CITY: FARMINGTON HILLS STATE: MI ZIP: 48335 FORMER COMPANY: FORMER CONFORMED NAME: REXAHN PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20050516 FORMER COMPANY: FORMER CONFORMED NAME: CORPORATE ROAD SHOW DOT COM INC DATE OF NAME CHANGE: 20030423 DEFA14A 1 brhc10038391_defa14a.htm DEFA14A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 14A


Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
(Amendment No.   )
 
Filed by the Registrant ☒
 
Filed by a party other than the Registrant ☐
 
Check the appropriate box:

☐
Preliminary Proxy Statement

☐
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐
Definitive Proxy Statement

☒
Definitive Additional Materials

☐
Soliciting Material Under § 240.14a-12
 
Ocuphire Pharma, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 
Payment of Filing Fee (Check all boxes that apply):

☒
No fee required

☐
Fee paid previously with preliminary materials

☐
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11

OCUPHIRE PHARMA, INC.
SUPPLEMENTAL MATERIAL TO OUR PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 13, 2022
 
This Supplement dated June 2, 2022 amends and supplements the Proxy Statement of Ocuphire Pharma, Inc. (“we”, “our” or the “Company”) dated April 27, 2022 (the “Proxy Statement”) with the following information:
 
Engagement of Proxy Solicitor
 
On June 2, 2022, we engaged Alliance Advisors, LLC (“Alliance Advisors”), to provide supplemental assistance in the solicitation of proxies, including proxy process related advice and informational support, at a cost of $7,500, plus reimbursement of expenses. We have paid and will pay other costs of soliciting votes in connection with the Proxy Statement. If stockholders need assistance with casting or changing their vote, they should contact Alliance Advisors at 866-407-1972.
 
Important Information
 
The Company has filed the definitive Proxy Statement with the Securities and Exchange Commission (the “SEC”) and has furnished to its stockholders the Proxy Statement in connection with the solicitation of proxies for its Annual Meeting. The Company advises its stockholders to read the Proxy Statement relating to the Annual Meeting, as amended and supplemented by this Supplement, because it contains important information. Stockholders may obtain a free copy of the Proxy Statement and other documents that the Company files with the SEC at the SEC’s website at www.sec.gov.